Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

7
CANADA STOCKS - TSX rises 0.40 percent, best day in a week

6h reuters
NEW YORK, July 19 (Reuters) - * The Toronto Stock Exchange’s S&P/TSX rose 65.61 points, or 0.40 percent, to 16,543.01, its biggest daily percentage gain since July 12. * Leading the index were TransCanada Corp, up 5.4 percent, Guyana Goldfields Inc, up 4.8 percent, and BlackBerry Ltd , higher by 4.3 percent. * Lagging shares were First Quantum Minerals Ltd, down 7.5 percent, Parex Resources Inc, down 5.
ENBBF TRP PXT GUY PARXF ACBFF ENB BBRY GUYFF ENB ACB APH BDRPF FQVLF EBBNF APHQF GYGC FQM

19
89 Champions, Contenders, And Challengers Rank As Wall St. Dividend Stars For July

22h seekingalpha
Champion dividend stocks sustain 25 or more annual dividend increases; Contenders show 10-24; Challengers have 5-9. WallStar selections all show .5% or higher price target upsides.
PM HMLP ETE GLOP ENB ANDX PBFX DKL SUN EBBNF MO ENBBF PEGI TLP NRZ GLOP.PRA GLOP.PRB SRLP ENB TCP ORI SIR PEG HMLP.PRA

1
Aecon Group joint venture wins Enbridge Line 3 replacement contract

2018-07-18 thestar
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
AEGXF ENBBF ENB EBBNF ARE ENB

3
TransCanada Says Blast-damaged Leach Natgas Pipe Back in Service on July 15

2018-07-13 rigzone
July 13 (Reuters) - TransCanada Corp's Columbia Gas Transmission expects the section of the Leach Xpress natural gas pipeline damaged in a blast in West Virginia in early June to return to service on July 15.
ENBBF ETP.PRC TRP KMI.WS RRL ENB RRS RGRLF RRC ENB ETP KMI.PRA RGRYY KMI TRI EBBNF KMR CVB KMRFZ

3
TransCanada says blast-damaged Leach natgas pipe back in service on July 15

2018-07-13 reuters
(Reuters) - TransCanada Corp’s Columbia Gas Transmission expects the section of the Leach Xpress natural gas pipeline damaged in a blast in West Virginia in early June to return to service on July 15.
ENBBF ETP.PRC TRP KMI.WS RRL ENB RRS RGRLF RRC ENB ETP KMI.PRA RGRYY KMI EBBNF KMR CVB KMRFZ

2
Halfway home, Bank of Canada sees the economy getting a refuel

2018-07-12 reuters
TORONTO/OTTAWA, July 12 (Reuters) - Having cut interest rates in 2015 to counter the oil slump, the Bank of Canada is now looking for a handoff from housing to energy as a source of growth, hoping higher prices can cushion the impact global trade tension has on exports and investment.
ENBBF ENB TRP KML EBBNF ENB

48
SDRL / Seadrill Limited - Stock Institutional Ownership and Shareholders - Fintel.io

2018-07-12 fintel.io
This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
ENB ENBBF CVX NOV SDRL EBBNF ENB RIG SGAZF

64
The Zacks Analyst Blog Highlights: Enbridge, Chevron, Core Laboratories N.V. and National Oilwell Varco

2018-07-11 zacks
Chicago, IL – July 11, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Enbridge Inc. (ENB - Free Report) , Chevron Corp. (CVX - Free Report) , Core Laboratories N.V. (CLB - Free Report) and National Oilwell Varco, Inc.
LPLA MOV NOV IBKR DTK MOVAA RDSB ENB LSTR SFIX RDSA HOLI CLB SDRL EBBNF RYDAF SCHW.PRBCL NBR.PRA ENBBF RDS.B RDS.A SCHN NBR SE ENB BHI CVX RYDBF URBN PETS

5
3 High-Yield Blue Chips That Could Make You Rich

2018-07-10 seekingalpha
The midstream industry is one of the most despised on Wall Street and is now in its fourth year of a bear market.
BAMGF ENBBF EBGUF XOM ENB EPD SEP ENB EBBNF BIP EEP MMP BAMKF BAM

1
Canadian Oil Executives Downplay Transportation Bottlenecks

2018-07-10 rigzone
CALGARY, July 10 (Reuters) - Executives at Canada's largest integrated oil and gas producers on Tuesday downplayed the severity of transportation bottlenecks to move oil in the near term, citing existing pipeline commitments and refining capabilities.
HSE ENB ENBBF CVE IMO CVE EBBNF ENB HUSKF IMO SU SU

56
Oil & Gas Stock Roundup: Enbridge's Midstream Sale, Chevron's North Sea Plans & More

2018-07-10 zacks
On the news front, Enbridge Inc. (ENB - Free Report) struck a pact to unload its Canadian natural gas gathering and processing businesses C$4.31 billion ($3.3 billion), while Chevron Corp. (CVX - Free Report) plans to put most of its oil and gas fields in the ageing North Sea for sale.
NBR.PRA ENBBF RDS.B RDS.A UNP NOV DTK RDSB VLO ENB RDSA CLB NBR SE COP ENB BHI CVX SDRL RYDBF EBBNF RYDAF

1
Oilsands execs see brighter future with approval of Line 3 pipeline project

2018-07-10 cbc.ca
Executives from the biggest oilsands companies in Canada say concerns about getting their products to market are starting to ease in the wake of the regulatory approval of Enbridge Inc.'s $9-billion Line 3 pipeline replacement project.
ENBBF CVE IMO ENB HUSKF IMO SU HSE ENB CNQ CVE EBBNF SU

1
CEO: Canada's Husky Energy Has Excess Oil Pipeline Capacity To US

2018-07-10 rigzone
CALGARY, July 10 (Reuters) - Husky Energy Inc has excess oil pipeline capacity to the United States from Canada and has enough capacity locked in to ship crude until about 2021, Chief Executive Rob Peabody said on Tuesday.
HSE ENBBF ENB EBBNF ENB HUSKF

1
DRGDF / Detour Gold Corp. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-07-09 fintel.io
Detour Gold Corp. (OTC:DRGDF) has 4 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 7,887,669 shares. Largest shareholders include Tocqueville Asset Management L.p., Hexavest Inc., Old Mission Capital, Llc, and Taylor Wealth Management Partners. Detour Gold Corp. (OTC:DRGDF) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size.
ENB ENBBF PVG DGC MEG MEGEF PVG EBBNF DRGDF ENB

11
MLPs: Delayed Fuse

2018-07-09 seekingalpha
In a rising broad market and a mixed commodity price backdrop, midstream stocks traded up but lagged the S&P 500 and utilities this week. Recent midstream corporation and utility outperformance has helped the Alerian Energy Infrastructure Index (AMEI) cut into the YTD lead the Alerian MLP Index has maintained since the MLP spike in January.
BKEP TGE PAGP SMLP ENB KEY IPL TEP BPL TEGP CEQP NSH OKE.WI EBBNF OKE BIP MMP IPPLF ENBBF BWP NS.PRC ENB NS.PRB PPL SEMG NS NS.PRA

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 29250N955